These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 17646224)

  • 1. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels.
    Chin KM; Channick RN; Kim NH; Rubin LJ
    Chest; 2007 Sep; 132(3):786-92. PubMed ID: 17646224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension].
    Nakayama T; Ishikita T; Matsuura H; Saji T
    J Cardiol; 2001 Nov; 38(5):263-71. PubMed ID: 11729726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
    Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
    Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension.
    Leuchte HH; Holzapfel M; Baumgartner RA; Ding I; Neurohr C; Vogeser M; Kolbe T; Schwaiblmair M; Behr J
    J Am Coll Cardiol; 2004 Mar; 43(5):764-70. PubMed ID: 14998614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the Need for Upfront Combination Therapy in Pulmonary Arterial Hypertension.
    Bajwa AA; Qureshi T; Shujaat A; Seeram V; Jones LM; Al-Saffar F; Cury JD
    J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):395-400. PubMed ID: 25613465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretion patterns of brain natriuretic peptide and atrial natriuretic peptide in patients with or without pulmonary hypertension complicating atrial septal defect.
    Nagaya N; Nishikimi T; Uematsu M; Kyotani S; Satoh T; Nakanishi N; Matsuo H; Kangawa K
    Am Heart J; 1998 Aug; 136(2):297-301. PubMed ID: 9704693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension.
    Andreassen AK; Wergeland R; Simonsen S; Geiran O; Guevara C; Ueland T
    Am J Cardiol; 2006 Aug; 98(4):525-9. PubMed ID: 16893710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension.
    Nagaya N; Nishikimi T; Uematsu M; Satoh T; Kyotani S; Sakamaki F; Kakishita M; Fukushima K; Okano Y; Nakanishi N; Miyatake K; Kangawa K
    Circulation; 2000 Aug; 102(8):865-70. PubMed ID: 10952954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension.
    Chin KM; Channick RN; de Lemos JA; Kim NH; Torres F; Rubin LJ
    Chest; 2009 Jan; 135(1):130-136. PubMed ID: 18719056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catecholamine support at the initiation of epoprostenol therapy in pulmonary arterial hypertension.
    Akagi S; Ogawa A; Miyaji K; Kusano K; Ito H; Matsubara H
    Ann Am Thorac Soc; 2014 Jun; 11(5):719-27. PubMed ID: 24716663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain natriuretic peptide is a prognostic parameter in chronic lung disease.
    Leuchte HH; Baumgartner RA; Nounou ME; Vogeser M; Neurohr C; Trautnitz M; Behr J
    Am J Respir Crit Care Med; 2006 Apr; 173(7):744-50. PubMed ID: 16415273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension.
    Nagaya N; Sasaki N; Ando M; Ogino H; Sakamaki F; Kyotani S; Nakanishi N
    Chest; 2003 Feb; 123(2):338-43. PubMed ID: 12576349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension.
    Leuchte HH; Holzapfel M; Baumgartner RA; Neurohr C; Vogeser M; Behr J
    Chest; 2005 Oct; 128(4):2368-74. PubMed ID: 16236896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension.
    Takatsuki S; Wagner BD; Ivy DD
    Congenit Heart Dis; 2012; 7(3):259-67. PubMed ID: 22325151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide in evaluation of respiratory failure in critically ill patients.
    Jefic D; Lee JW; Jefic D; Savoy-Moore RT; Rosman HS
    Chest; 2005 Jul; 128(1):288-95. PubMed ID: 16002948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of obesity on B-type natriuretic peptide levels in patients with pulmonary arterial hypertension.
    Batal O; Faulx M; Krasuski RA; Khatib OF; Hammel JP; Hussein AA; Minai OA; Dweik RA
    Am J Cardiol; 2012 Sep; 110(6):909-14. PubMed ID: 22683040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry.
    Frantz RP; Farber HW; Badesch DB; Elliott CG; Frost AE; McGoon MD; Zhao C; Mink DR; Selej M; Benza RL
    Chest; 2018 Jul; 154(1):126-135. PubMed ID: 29355551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease.
    Thomas IC; Glassner-Kolmin C; Gomberg-Maitland M
    Int J Cardiol; 2013 Oct; 168(4):4117-21. PubMed ID: 23890862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit.
    Forfia PR; Watkins SP; Rame JE; Stewart KJ; Shapiro EP
    J Am Coll Cardiol; 2005 May; 45(10):1667-71. PubMed ID: 15893185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.